GlassScriptPhysician profile
William J Booth
NPI 1386896710
$2,102.81
in general payments reported to CMS, 2019-2025
23 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $156 · 2023: $319 · 2024: $165 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $484.84 | 2021-2025 | Penmenvy, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $354.31 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Mannkind Corporation | $154.58 | 2025 | |
| Collegium Pharmaceutical, INC. | $139.91 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $121.17 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $121.17 | 2025 | |
| Lundbeck LLC | $112.50 | 2025 | Rexulti |
| Cranial Technologies, INC | $81.26 | 2023-2025 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.19 | 2025 | Jardiance |
| Seqirus USA INC | $70.77 | 2021-2025 | Flucelvax Quadrivalent, Flucelvax |
| Supernus Pharmaceuticals, INC. | $58.57 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $52.93 | 2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $40.94 | 2021 | |
| Biomerieux INC | $36.00 | 2025 | |
| Corium, LLC | $32.63 | 2024 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.10 | 2021-2025 | |
| Sanofi Pasteur INC. | $29.24 | 2021 | |
| Soleno Therapeutics, INC. | $22.27 | 2025 | Vykat Xr |
| Phadia US INC. | $19.93 | 2023 | Immunocap |
| Verrica Pharmaceuticals INC. | $18.95 | 2024 | Ycanth |
| Genentech USA, INC. | $15.01 | 2021 | |
| Tris Pharma INC | $13.98 | 2025 | Dyanavel Xr |
| Ironwood Pharmaceuticals, INC | $13.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.